Iovance Biotherapeutics's market cap is currently ―. The company's EPS TTM is $; its P/E ratio is ―; Iovance Biotherapeutics is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.42. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 482.00K	$ 469.00K	$ 238.00K	-	-
Gross Profit	$ -3.88M	$ -3.87M	$ 238.00K	-	-
EBIT	-	$ -115.00M	$ -104.95M	$ -107.37M	$ -107.04M
EBITDA	-	-	$ -97.02M	$ -102.65M	$ -101.98M
Net Income Common Stockholders	$ -116.36M	$ -113.80M	$ -106.53M	$ -107.37M	$ -105.32M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 279.87M	$ 361.37M	$ 250.89M	$ 626.29M	$ 471.85M
Total Assets	$ 780.35M	$ 852.32M	$ 757.29M	$ 824.77M	$ 663.98M
Total Debt	$ 75.86M	$ 79.48M	$ 80.71M	$ 83.23M	$ 85.45M
Net Debt	$ -204.00M	$ -281.90M	$ -170.18M	$ -543.07M	$ -386.40M
Total Liabilities	$ 195.74M	$ 178.31M	$ 178.72M	$ 157.89M	$ 164.34M
Stockholders Equity	$ 584.61M	$ 674.01M	$ 578.57M	$ 666.88M	$ 499.64M
Cash Flow	-
Free Cash Flow	-	-	$ -103.47M	$ -105.51M	$ -80.72M
Operating Cash Flow	$ -83.90M	$ -84.10M	$ -93.95M	$ -99.84M	$ -77.70M
Investing Cash Flow	$ -72.84M	$ -79.01M	$ -156.78M	$ 153.40M	$ 461.00K
Financing Cash Flow	$ 962.00K	$ 202.80M	$ 1.02M	$ 258.17M	$ 190.57M

Currency in USD

Iovance Biotherapeutics Earnings and Revenue History

Income Statement >

Iovance Biotherapeutics Debt to Assets

Balance Sheet >

Iovance Biotherapeutics Cash Flow

Cash Flow >

Iovance Biotherapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing